Shinoda et al.
1.74 mmol) with concd HCl (1.5 mL) in MeOH (10 mL). After
stirring for 2 h, the solvent was removed. White hygroscopic
precipitate was obtained (571 mg, 65%) by adding Et2O to the
MeOH solution: IR (KBr) ν 1653, 1551, and 1071 cm-1 1H
;
NMR (D2O) δ 2.8 (br s, 8H), 2.9-3.1 (8H), 3.36 (s, 2H), 4.22
(s, 2H), 7.08 (d, 2H, J ) 8.1 Hz) and 7.41 (d, 2H, J ) 8.2 Hz);
13C NMR (D2O) δ 42.9, 43.3, 45.1, 50.4, 56.0, 129.7, 132.3,
137.4, and 173.8; MS (FAB, pos) m/z 398 (M + H+). Anal. Calcd
for C17H28N5OBr‚3HCl‚1.5H2O: C, 38.18; H, 6.41; N, 13.10.
Found: C, 38.33; H, 6.41; N, 13.08.
1-(4-Bromophenyl)methylcarbamoylmethyl-4,7,10-tris-
(cholesteryloxycarbonylmethyl)-1,4,7,10-tetraazacy-
clododecane (2)-NaCl complex was prepared as described
below. 1-(4-Bromophenyl)methylcarbamoylmethyl-1,4,7,10-
tetraazacyclododecane‚3HCl (151 mg, 0.298 mmol) and
Na2CO3 (328 mg, 3.09 mmol) were refluxed in CH3CN (7 mL)
for 1 h under N2. Cholesterol chloroacetate (631 mg, 1.36
mmol) dissolved in CHCl3 (10 mL) was added dropwise and
refluxed for 50 h. After solvent was removed, CH2Cl2 was
added, and the insoluble inorganic materials were filtered
using cerite. After evaporation, the residue was repeatedly
reprecipitated from CH2Cl2/hexane followed by centrifugation
to remove excess cholesterol chloroacetate. Colored impurities
were removed using charcoal (160 mg × 2) in CH2Cl2 solution
which finally gave colorless crystals from CH2Cl2/Et2O (230
mg, 42%): mp 198-200 °C; [R]27D ) -63 (c ) 0.50, CHCl3); IR
(KBr) ν 1732, 1668, and 1213 cm-1; 1H NMR (CDCl3, 50 °C) δ
0.68 (s, 3H), 0.70 (s, 3H × 2), 0.87 (d, 18H, J ) 6.0 Hz), 0.92
(d, 6H, J ) 6.7 Hz), 0.94 (d, 3H, J ) 6.4 Hz), 0.96 (s, 3H), 0.98
(s, 6H), 0.9-1.2 (33H), 1.2-1.7 (33H), 1.7-2.1 (15H), 2.1-3.4
(25H), 3.62 (s, 2H), 4.28 (br s, 1H), 4.48 (br s, 1H), 4.62 (m,
3H), 5.10 (br s, 1H), 5.31 (m, 2H), 7.24 (m, 2H), 7.31 (m, 2H),
and 9.99 (br s, 1H); 13C NMR (CDCl3, 50 °C) δ 11.9, 12.1, 18.8,
18.9, 19.0, 19.2, 19.3, 21.2, 21.3, 22.6, 22.8, 22.8, 23.9, 24.0,
24.1, 24.1, 24.4, 24.5, 27.5, 27.9, 28.0, 28.1, 28.1, 28.2, 28.3,
31.9, 31.9, 32.0, 32.1, 32.3, 32.5, 35.8, 35.9, 35.9, 36.0, 36.3,
36.4, 36.6, 36.6, 36.7, 37.0, 37.1, 37.3, 38.0, 38.2, 38.3, 39.7,
39.9, 40.0, 40.1, 42.4, 42.5, 42.5, 50.1, 50.3, 50.4, 55.2, 55.2,
56.2, 56.4, 56.5, 56.9, 56.9, 57.1, 57.2, 75.5, 75.2, 75.6, 120.2,
123.0, 123.1, 129.6, 131.2, 139.1, 139.4, 139.9, 172.6, and
172.9; MS (FAB, pos) m/z 1699 (2 + Na+). Anal. Calcd for
FIGURE 7. Synthesis of armed cyclen 2.
) 1.5 Hz), 0.88 (d, 12H, J ) 1.7 Hz), 0.92 (d, 12H, J ) 6.3 Hz),
0.99 (s, 12H), 2.15-2.35 (br m, 4H), 2.40-2.70 (br m, 8H), 2.98
(br d, 4H, J ) 17.3 Hz), 3.25-3.45 (br m, 4H), 3.45 (br d, 4H,
J ) 17.1 Hz), 4.53 (br m, 4H), and 5.26 (br 4H); 13C NMR
(CDCl3) δ 11.93, 18.69, 19.08, 21.03, 22.54, 22.77, 23.57, 24.26,
27.64, 27.97, 28.13, 31.63, 32.49, 35.69, 36.20, 36.36, 36.90,
38.15, 39.57, 39.90, 42.32, 48.46, 50.34, 53.01, 54.80, 56.07,
57.23, 75.48, 122.49, 139.71, and 173.49. Anal. Calcd for
C
124H204N4O8‚NaCl‚5H2O: C, 73.46; H, 10.64; N, 2.76. Found:
C, 73.76; H, 10.49; N, 2.76.
1-(4-Bromophenyl)methylcarbamoylmethyl-4,7,10-tris-
(cholesteryloxycarbonylmethyl)-1,4,7,10-tetraazacy-
clododecane (2)-NaCl Complex (See Figure 7). N-(4-
Bromophenyl)methyl-2-chloroethanamide20 was synthe-
sized by mixing a CH2Cl2 (100 mL) solution of 4-(bromophen-
yl)methylamine (1.96 g, 8.81 mmol) and triethylamine (2.24
g, 22.1 mmol) with a CH2Cl2 solution (50 mL) of 2-chloroacetyl
chloride (1.51 g, 13.4 mmol) at 0 °C. After 1.5 h stirring at 0
°C, the organic phase was washed with water (100 mL), 1 M
hydrochloric acid (100 mL × 2) and sat. NaCl solution (100
mL), evaporated, and dried over MgSO4. Recrystallization from
CH2Cl2/hexane gave needle crystals (1.33 g, 5.07 mmol): 58%
yield; mp 124-125 °C; IR (KBr) ν 3270, 1661, 1558, 1245, and
796 cm-1; 1H NMR (CDCl3) δ 4.11 (s, 2H), 4.45 (d, 2H, J ) 6.1
Hz), 6.88 (br s, 1H), 7.18 (m, 2H), and 7.48 (m, 2H); 13C NMR
(CDCl3) δ 42.6, 43.2, 121.7, 129.5, 131.9, 136.3, and 165.9; MS
(FAB, pos) m/z 262 (M + H+).
C104H166BrN5O7‚NaCl‚(H2O)3.5: C; 69.40, H; 9.69, N; 3.89.
Found: C; 69.19, H; 9.38, N; 3.82.
Synthesis of Cholesteryl Morpholinoacetate (3). This
was similarly prepared by reaction of morpholine and choles-
terol chloroacetate (65%): mp 123-124 °C; [R]25 ) -30.4 (c
D
) 2.0, CHCl3); IR (KBr) ν 1729 cm-1; 1H NMR (CDCl3) δ 0.68
(s, 3H), 0.85 (d, 3H, J ) 1.3 Hz), 0.87 (d, 3H, J ) 1.3 Hz), 0.91
(d, 3H, J ) 6.4 Hz), 1.02 (s, 3H), 0.8-2.1 (m, 26H), 2.33 (d,
2H, J ) 7.7 Hz), 2.59, 3.75 (t x 2, 8H, J ) 4.7 Hz), 3.18 (s,
2H), 4.66 (br m, 1H), and 5.38 (d, 1H, J ) 4.4 Hz); 13C NMR
(CDCl3) δ 11.84, 18.70, 19.29, 21.01, 22.54, 22.80, 23.81, 24.26,
27.78, 28.00, 28.20, 31.84, 31.89, 35.78, 36.16, 36.57, 36.93,
38.11, 39.50, 39.71, 42.30, 50.00, 53.28, 56.12, 56.67, 59.90,
66.80, 74.73, 122.82, 139.44, and 169.49. Anal. Calcd for
C33H55NO3: C, 77.14; H, 10.79; N, 2.73. Found: C, 77.01; H,
10.77; N, 2.73.
1-(4-Bromophenyl)methylcarbamoylmethyl-4,7,10-tris-
(tert-butyloxycarbonyl)-1,4,7,10-tetraazacyclodode-
cane was prepared by the reaction of 1,4,7-tris(tert-butyl-
oxycarbonyl)-1,4,7,10-tetraazacyclododecane (993 mg, 2.10
mmol)21 and N-(4-bromophenyl)methyl-2-chloroethanamide
(822 mg, 3.14 mmol) in the presence of K2CO3 (647 mg, 4.68
mmol) and KI (156 mg, 0.940 mmol) in dry CH3CN (20 mL).
After refluxing for 15 h under N2, the solvent was evaporated
and the residue was dissolved in CH2Cl2 and filtered. The
filtrate was chromatographed on silica gel with CH2Cl2/AcOEt
(1/5, v/v) to give 1.26 g (85%) of amorphous product: IR (KBr)
Preparation of Self-Aggregates. An ethanol solution of
cholesterol-armed cyclen 1-NaCl complex (0.50 µmol/1 mL)
was diluted with Bis-Tris-HCl buffer solution (6.3 × 10-3 M,
pH ) 7.2). The resulting aqueous solution (H2O/EtOH )
80/20, v/v) was spectroscopically clear and gave no precipitate
for several days. Light scattering experiments indicated that
the particle sizes of the self-aggregates were slightly changed
(50-70 nm) after aging, centrifugation or other procedures.
The self-aggregate of morpholine derivative 3 was similarly
prepared, though it did not complex with Na+ cation. Ca2+ and
1
ν 1689, 1540, 1250, and 1167 cm-1; H NMR (CDCl3) δ 1.38
(br s, 18H), 1.48 (s, 9H), 3.19 (s, 2H), 3.37 + 3.47 (br s, 12H),
4.37 (d, 2H, J ) 6.1 Hz), 7.17 (m, 2H), 7.28 (br s, 1H), and
7.43 (m, 2H); 13C NMR (CDCl3) δ 28.3, 28.5, 42.6, 47.6, 50.0,
60.3, 80.0, 121.0, 129.5, 131.6, 137.6, 155.6, and 171.2; MS
(FAB, pos) m/z 698 (M + H+).
1-(4-Bromophenyl)methylcarbamoylmethyl-1,4,7,10-
tetraazacyclododecane‚3HCl was synthesized by deprotec-
tion of 1-(4-bromophenyl)methylcarbamoylmethyl-4,7,10-tris-
(tert-butyloxycarbonyl)-1,4,7,10-tetraazacyclododecane (1.22 g,
Y
3+ complexes with cyclen 1 were in situ prepared. When 1.5
equiv of Ca2+ triflate was typically mixed with free cyclen 1,
the cation complexation process was monitored by ESI-MS and
NMR measurements. After evaporation, the ethanol solution
of the complex was diluted with aqueous buffer solution. Both
(20) Watanabe, S.; Kataoka, T. Jpn. Tokkyo Koho. 1969, JP 44026847.
(21) Kimura, E.; Aoki, S.; Koike, T.; Shiro, M. J. Am. Chem. Soc.
1997, 119, 3068.
1842 J. Org. Chem., Vol. 70, No. 5, 2005